Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
Brand Name :
Synonyms :
Class :
Subcutaneous (Apokyn) Initial: 2mg SC as needed in a volume of 0.2 mL
Sublingual (Kynmobi) 10 mg SL, with a maximum allowance of up to 5 doses/day
The highest allowable individual dose is 30 milligrams
when both drugs are combined, there may be an increase in qtc interval  
QT-prolonging Strong may enhance the QTc-prolonging effect of delamanid
may enhance the QTc-prolonging effect of Fluorouracil Products
may increase the CNS depressant effect
may increase the CNS depressant effect
may have an increased QTc-prolonging effect when combined with domperidone
may have an increased CNS depressive effect when combined with CNS depressants
CNS depressants may have an increased CNS depressive effect when combined with flunitrazepam
may have an increased CNS depressant effect when combined with dexmedetomidine
may have an increased CNS depressant effect when combined with CNS depressants
may increase the CNS depressant effect of CNS depressants
may have an increased QTc-prolonging effect when combined with astemizole
may have an increased QTc-prolonging effect when combined with bedaquiline
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with chlorpromazine
may have an increased QTc-prolonging effect when combined with cisapride
may have an increased QTc-prolonging effect when combined with clofazimine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with clozapine
may have an increased QTc-prolonging effect when combined with dasatinib
hydroxyzine: they may increase the CNS depressant effect of CNS Depressants
lemborexant: they may increase the CNS depressant effect of CNS Depressants
may have an increased hypotensive effect when combined with apomorphine
nalmefene: they may decrease the therapeutic effect of Opioid Agonists
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of Buprenorphine
May enhance the QTc-prolonging effect of each other when combined
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
inotuzumab: they may enhance the QTc-prolonging effect of QTc-prolonging agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
oxolamine: they may increase the CNS depressant effect of CNS Depressants
amisulpride: they may increase the CNS depressant effect of CNS Depressants
ramosetron: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
amiodarone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pilsicainide HCL: they may increase the QTc-prolonging effect of QTc-prolonging Agents
linezolid: they may increase the CNS depressant effect of CNS Depressants
secretin: they may increase the CNS depressant effect of CNS Depressants
abciximab: it may decrease the excretion rate of abacavir CNS depressant
benoxaprofen: it may increase the risk of CNS depression
alpelisib: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
alosetron: it may increase the risk of CNS depression
albendazole: it may increase the risk of CNS depression
agomelatin: it may increase the risk of CNS depression
acyclovir: it may increase the risk of CNS depression
benzphetamine: it may increase the risk of CNS depression
benzydamine: it may increase the risk of CNS depression
cannabidiol: it may increase the risk of CNS depression
capsaicin: it may increase the risk of CNS depression
captopril: it may increase the risk of CNS depression
carbinoxamine: it may increase the risk of CNS depression
darunavir: it may increase the risk or severity of QTc prolongation
antiemetics increase the hypotensive effect of apomorphine
antiemetics increase the hypotensive effect of apomorphine
antiemetics increase the hypotensive effect of apomorphine
antiemetics increase the hypotensive effect of apomorphine
it may enhance the qtc interval when combined with lofexidine
when used together, entrectinib and apomorphine both increase the QTc interval
when used together, encorafenib and apomorphine both increase the QTc interval
when both drugs are combined, there may be increase in both increase QTc interval  arsenic trioxide 
when both drugs are combined, there may be increase in both increase QTc interval  arsenic trioxide 
antiemetics increase the hypotensive effect of apomorphine
antiemetics increase the hypotensive effect of apomorphine
antiemetics increase the hypotensive effect of apomorphine
may enhance the QTc-prolonging effect of Nilotinib
may increase the QTc interval when combined
azelastine/fluticasone intranasalÂ
may increase the CNS depressant effect
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of orphenadrine
it increases the effect of CNS depressants
CNS depressants increase the effect of paraldehyde
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with flunarizine
may have an increased QTc-prolonging effect when combined with flupentixol
may have an increased QTc-prolonging effect when combined with levoketoconazole
It may enhance QTc interval when combined with pentamidine
QT-prolonging Agents (Highest Risk) may increase Citalopram's ability to prolong QTc
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
thiazide and it’s like diuretics increase the effect of QTc prolongation
May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
moxifloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
nilotinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
piperaquine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
furosemide: it may increase the CNS depressant effect of CNS Depressants
aclidinium: they may increase the CNS depressant effect of CNS Depressants
mequitazine: they may increase the CNS depressant effect of CNS Depressants
cimetropium: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
pitolisant: they may increase the CNS depressant effect of CNS Depressants
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when amisulpride is used in combination
dopamine agonists' efficacy will decrease when metoclopramide is used in combination
the efficacy of dopamine agonists will be decreased when sulpride is used in combination
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
may increase the harmful effects of CNS depressants
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
CNS Depressants may enhance the CNS depressant effect of Opioid agonists
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
may enhance the CNS depressant effect of Opioid Agonists
It may enhance sedation when combined with tramadol
It may enhance sedation when combined with codeine
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
It may enhance sedation when combined with oxycodone
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may have an increased effect of CNS depressant when combined with cannabinoid products
may have an increased effect of CNS depressant when combined with cannabinoid products
The potential for increased CNS depression risk or seriousness occurs when apomorphine is used together with pinazepam
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
they decrease the effect of each other by pharmacodynamic antagonism
When apomorphine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with apomorphine, There is a risk or seriousness of CNS depression is enhanced
When apomorphine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when apomorphine is used together with fencamfamin
When apomorphine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When apomorphine is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
When chlordiazepoxide is used together with apomorphine, this leads to enhanced risk or seriousness of CNS depression
When apomorphine is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When ponesimod is used together with apomorphine, this leads to enhanced risk or seriousness of bradycardia
When apomorphine is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When apomorphine is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
When emylcamate is used together with apomorphine, this leads to enhanced risk or seriousness of CNS depression
When apomorphine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with apomorphine, this leads to enhanced risk or seriousness of CNS depression
may have an increased Effect of CNS depressant when combined with alcohol
apomorphine: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
the risk or extent of CNS depression can be raised when apomorphine is combined with clidinium
apomorphine: it may decrease the metabolism of cerivastatin
when both drugs are combined, both increase the QTC interval   
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased QTC interval  
when both drugs are combined, there may be an increased QTC interval  
lisuride may enhance the CNS depressant effect of CNS Depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
when combined, it may increase sedation
may increase the QTc interval
when combined, it may increase sedation
glycopyrrolate inhaled and formoterolÂ
may increase the QTc interval when combined
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the adverse/toxic effect of other CNS depressants
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased CNS depressant effect when combined with brexanolone
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the efficacy of cannabinoid-containing products
CNS depressants increase the efficacy of cannabinoid-containing products
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may increase the toxic effect of CNS depressants
lofexidine: they may increase the CNS depressant effect of CNS Depressants
pramipexole: they may increase the sedative effect of CNS Depressants
may have an increased Effect of a CNS depressant when combined with methotrimeprazine
may increase the QTc-prolonging effect when combined
may increase the QTc-prolonging effect of each other when combined
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with dabrafenib
may have an increased QTc-prolonging effect when combined with fluorouracil products
may have an increased QTc-prolonging effect when combined with haloperidol
may have an increased QTc-prolonging effect when combined with ondansetron
may have an increased QTc-prolonging effect when combined with pentamidine
may have an increased effect of CNS depression when combined with Apomorphine
The sedative effect of metyrosine might be intensified by CNS depressants
hydroxyzine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pacritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
chloroprocaine: they may increase the CNS depressant effect of CNS Depressants
ixabepilone: they may increase the CNS depressant effect of CNS Depressants
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
benzyl alcohol: they may increase the CNS depressant effect of CNS Depressants
bromopride: they may increase the CNS depressant effect of CNS Depressants
dimethindene: they may increase the CNS depressant effect of CNS Depressants
kava: they may increase the CNS depressant effect of CNS Depressants
flecainide: they may increase the CNS depressant effect of CNS Depressants
adverse effects or toxic effects of lacosamide are increased by antiarrhythmic agents when used in combination
glucagon: they may increase the CNS depressant effect of CNS Depressants
hyaluronidase: they may increase the CNS depressant effect of CNS Depressants
tedizolid: they may increase the CNS depressant effect of CNS Depressants
alfuzosin: they may increase the CNS depressant effect of CNS Depressants
dexketoprofen: they may increase the CNS depressant effect of CNS Depressants
aprotinin: they may increase the CNS depressant effect of CNS Depressants
side effects of bupropion are increased when dopamine agonist is combined
may increase the CNS depressant effect of CNS depressants
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abatacept: it may decrease the excretion rate of abacavir CNS depressant
alvimopan: it may increase the risk or severity of CNS depression
carmustine: it may increase the risk or severity of CNS depression
carprofen: it may increase the risk or severity of CNS depression
carvedilol: it may increase the risk or severity of CNS depression
dalfampridine: it may increase the risk or severity of CNS depression
cariprazine: it may increase the risk or severity of CNS depression
cetirizine: it may increase the risk or severity of CNS depression
celiprolol: it may increase the risk or severity of CNS depression
ajmaline: it may increase the risk or severity of CNS depression
apomorphine: it may increase the risk or severity of CNS depression
arformoterol: it may decreased the serum concentration of CNS depressants
oxybuprocaine: it may increase the metabolism of CNS depressants
axitinib: it may increase the metabolism of CNS depressants
the therapeutic effect of apomorphine may be reduced
the risk of CNS depression may be increased
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
the hazard or seriousness of QTc prolongation can be heightened when apomorphine is combined with digitoxin
amitriptyline: it may increase the risk or severity of QTc prolongation agents
benserazide: it may increase the risk or severity of QTc prolongation agents
it increases the effect of CNS depressants
CNS depressants increase the effect of zolpidem
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
CNS depressants increase the effect of opioid agonists serotonergic opioids
CNS depressants increase the effect of opioid agonists serotonergic opioids
CNS depressants increase the effect of opioid agonists serotonergic opioids
CNS depressants increase the effect of opioid agonists serotonergic opioids
it increases the toxicity of muscle relaxants
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
